Abstract
Blood concentrations of dopexamine were measured in five female patients during and after orthotopic liver transplantation. Each patient received a continuous infusion of the drug (2 micrograms kg-1 min-1), starting at induction of anaesthesia and finishing 48 h afterwards. Blood concentrations of dopexamine increased rapidly at the start of the infusion, to a mean (range) value of 64 (40-150) ng ml-1 after 20 min. Blood concentrations of dopexamine increased further during the anhepatic period of surgery, to 236 (180-410) ng ml-1. On reperfusion of the donor liver, concentrations of dopexamine decreased rapidly, reaching similar values to the maximum seen during the dissection period. Steady-state was not reached during either the dissection or anhepatic periods. From 1-2 h after revascularisation the mean (range) steady-state concentration was 85 (69-102) ng ml-1 corresponding to a mean (range) clearance of 24 (20-29) ml min-1 kg -1. These results suggest that the liver plays a significant role in the clearance of dopexamine.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bodenham A., Quinn K., Park G. R. Extrahepatic morphine metabolism in man during the anhepatic phase of orthotopic liver transplantation. Br J Anaesth. 1989 Oct;63(4):380–384. doi: 10.1093/bja/63.4.380. [DOI] [PubMed] [Google Scholar]
- Brown R. A., Dixon J., Farmer J. B., Hall J. C., Humphries R. G., Ince F., O'Connor S. E., Simpson W. T., Smith G. W. Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors. Br J Pharmacol. 1985 Jul;85(3):599–608. doi: 10.1111/j.1476-5381.1985.tb10554.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Carmichael F. J., Lindop M. J., Farman J. V. Anesthesia for hepatic transplantation: cardiovascular and metabolic alterations and their management. Anesth Analg. 1985 Feb;64(2):108–116. [PubMed] [Google Scholar]
- Dawson J. R., Thompson D. S., Signy M., Juul S. M., Turnbull P., Jenkins B. S., Webb-Peploe M. M. Acute haemodynamic and metabolic effects of dopexamine, a new dopaminergic receptor agonist, in patients with chronic heart failure. Br Heart J. 1985 Sep;54(3):313–320. doi: 10.1136/hrt.54.3.313. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gray P. A., Bodenham A. R., Park G. R. A comparison of dopexamine and dopamine to prevent renal impairment in patients undergoing orthotopic liver transplantation. Anaesthesia. 1991 Aug;46(8):638–641. doi: 10.1111/j.1365-2044.1991.tb09711.x. [DOI] [PubMed] [Google Scholar]
- Park G. R., Manara A. R., Dawling S. Extra-hepatic metabolism of midazolam. Br J Clin Pharmacol. 1989 May;27(5):634–637. doi: 10.1111/j.1365-2125.1989.tb03429.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Polson R. J., Park G. R., Lindop M. J., Farman J. V., Calne R. Y., Williams R. The prevention of renal impairment in patients undergoing orthotopic liver grafting by infusion of low dose dopamine. Anaesthesia. 1987 Jan;42(1):15–19. doi: 10.1111/j.1365-2044.1987.tb02938.x. [DOI] [PubMed] [Google Scholar]
- Saccà L., Hendler R., Picardi A., Sherwin R. S. Splanchnic and renal contribution to disposal of infused epinephrine in humans. Am J Physiol. 1986 Sep;251(3 Pt 1):E285–E289. doi: 10.1152/ajpendo.1986.251.3.E285. [DOI] [PubMed] [Google Scholar]